Deutenzalutamide, an Oral Deuterated Androgen Receptor Inhibitor, Vs Placebo for Patients with Mcrpc Who Have Experienced Treatment Failure with Abiraterone and Docetaxel: Results of the HC-1119-04 Phase 3 Trial
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要